Syntellix is a highly innovative med-tech and biomaterials pioneer, specializing in the research, development, manufacturing and sales of bio-absorbable magnesium-based implants. Stable as traditional titanium or stainless steel, its MAGNEZIX® implants offer the huge advantage that they turn into bone tissue in due time. Thus, they are avoiding the patients’ burden to live with a foreign material inside the body forever, including possible long-term risks, or of having to suffer a second surgery for implant removal with the associated infection, refracture and anesthesia risks. Proven in tens of thousands of surgeries, and evaluated positively by more than 45 scientific publications, its disruptive MAGNEZIX® devices are even described as being “clinically superior” to conventional titanium (or steel). In a nutshell: Half the time, half the cost, half the pain, half the suffering and half the infection risk. Syntellix has already received product approvals for more than 70 countries and regions with 3.8 billion potential patients. The highly respected U.S. FDA has even granted its MAGNEZIX® CS 3.2 key implant the designation of a “Breakthrough Device”. Syntellix intends to accelerate international growth further, and to give patients, doctors, potential partners and investors the chance to join the Syntellix community and participate in the value creation potential of its globally unique, patent-protected, cutting-edge technology.